All In Biotech

Drug Trial Radar · NCT00295542

Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study).

Last checked: Nov 19, 2026Latest source record: Apr 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,344 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,344

Actual

Start

Mar 2000

Primary completion

Apr 2009

Study completion Apr 2009

Sponsor

Lead sponsor
University of VigoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hospital Clinico Universitario de Santiago; Ministry of Work and Welfare - Xunta de Galicia; Ministerio de Educacion y Ciencia, Spain
First posted
Feb 23, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The MAPEC study was designed to investigate whether normalizing the circadian blood pressure profile towards a more dipper pattern (increasing the diurnal/nocturnal ratio of blood pressure) by the use of Chronotherapy (that is, taking into account the time of day of administration of antihypertensive medications) reduces cardiovascular risk.

Conditions

  • Hypertension

Interventions

  • Ambulatory blood pressure monitoringDevice

    Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

  • Chronotherapy, timing of antihypertensive medicationProcedure

    Comparison of effects of awakening versus bedtime dosing

  • ACEI (including spirapril, enalapril, quinapril, lisinopril)Drug

    Treatment at awakening versus bedtime

  • ARB (including valsartan, telmisartan, olmesartan)Drug

    Treatment at awakening versus bedtime

  • beta blockers (including nebivolol, atenolol, carvedilol)Drug

    Treatment at awakening versus bedtime

  • diuretics (torasemide, indapamide, HTCZ) and doxazosinDrug

    Treatment at awakening versus bedtime

  • Combination therapy in essential hypertensionProcedure

    Treatment at awakening versus bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prognostic value of ABPM, impact of changes in ambulatory BP and impact of circadian time of antihypertensive treatment in cardiovascular, cerebrovascular and renal risk assessment.Time frame: Five years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Clinico Universitario

    Santiago de Compostela, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.